Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women's Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Gaithersburg, MD.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Braskem SA engages in the manufacture of petrochemicals and other related products. It operates through the following segments: Brazil, USA, and Europe and Mexico. The Brazil segment includes production and sale of chemicals, supply of electricity, and production and sale of PE. The USA and Europe segment involves production, operation, and sale of polypropylene in the United States and Germany. The Mexico segment comprises production, operation, and sale of ethylene, high-density polyethylene and low-density polyethylene in Mexico. The company was founded in August 2002 and is headquartered in Butanta, Brazil.

Ctrl Group Ltd. is a holding company, which engages in the provision of marketing and advertising services. It offers one-stop advertising services to clients throughout the entire advertising process, which comprises the planning, creating, launching, managing, and performance monitoring of the advertisements. The company was founded by Kai Kwan Lam, Chi Fung Lau, and Chun Pong Siu on May 13, 2022 and is headquartered in Hong Kong.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

PubMatic, Inc. engages in the provision of specialized cloud infrastructure platform for advertising transactions. Its technology and infrastructure caters both Internet content creators and advertisers. It operates through the following geographical segments: United States, EMEA, APAC, and Rest of the World. The company was founded by Anand Das, Rajeev Kumar Goel, Amar Goel, and Mukul Kumar in 2006 and is headquartered in Redwood City, CA.